Cover Image

Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of LKB1 and activation of AMPK in PDACs

Pancreatic ductal adenocarcinoma (PDAC) clinically has a very poor prognosis. No small molecule is available to reliably achieve cures. Meisoindigo is chemically related to the natural product indirubin and showed substantial efficiency in clinical chemotherapy for CML in China. However, its effect...

Full description

Saved in:
Bibliographic Details
Main Authors: Cheng, Xinlai (Author) , Kim, Jee Young (Author) , Ghafoory, Shahrouz (Author) , Duvaci, Tijen (Author) , Rafiee, Roya (Author) , Theobald, Jannick (Author) , Alborzinia, Hamed (Author) , Holenya, Pavlo (Author) , Fredebohm, Johannes (Author) , Merz, Karl-Heinz (Author) , Mehrabi, Arianeb (Author) , Hafezi, Mohammadreza (Author) , Saffari, Arash (Author) , Eisenbrand, Gerhard (Author) , Hoheisel, Jörg D. (Author) , Wölfl, Stefan (Author)
Format: Article (Journal)
Language:English
Published: 4 February 2016
In: Molecular oncology
Year: 2016, Volume: 10, Issue: 6, Pages: 806-824
ISSN:1878-0261
DOI:10.1016/j.molonc.2016.01.008
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.molonc.2016.01.008
Verlag, lizenzpflichtig, Volltext: https://febs.onlinelibrary.wiley.com/doi/abs/10.1016/j.molonc.2016.01.008
Get full text
Author Notes:Xinlai Cheng, Jee Young Kim, Shahrouz Ghafoory, Tijen Duvaci, Roya Rafiee, Jannick Theobald, Hamed Alborzinia, Pavlo Holenya, Johannes Fredebohm, Karl-Heinz Merz, Arianeb Mehrabi, Mohammadreza Hafezi, Arash Saffari, Gerhard Eisenbrand, Jörg D. Hoheisel, Stefan Wölfl
Description
Summary:Pancreatic ductal adenocarcinoma (PDAC) clinically has a very poor prognosis. No small molecule is available to reliably achieve cures. Meisoindigo is chemically related to the natural product indirubin and showed substantial efficiency in clinical chemotherapy for CML in China. However, its effect on PDAC is still unknown. Our results showed strong anti-proliferation effect of meisoindigo on gemcitabine-resistant PDACs. Using a recently established primary PDAC cell line, called Jopaca-1 with a larger CSCs population as model, we observed a reduction of CD133+ and ESA+/CD44+/CD24+ populations upon treatment and concomitantly a decreased expression of CSC-associated genes, and reduced cellular mobility and sphere formation. Investigating basic cellular metabolic responses, we detected lower oxygen consumption and glucose uptake, while intracellular ROS levels increased. This was effectively neutralized by the addition of antioxidants, indicating an essential role of the cellular redox balance. Further analysis on energy metabolism related signaling revealed that meisoindigo inhibited LKB1, but activated AMPK. Both of them were involved in cellular apoptosis. Additional in situ hybridization in tissue sections of PDAC patients reproducibly demonstrated co-expression and -localization of LKB1 and CD133 in malignant areas. Finally, we detected that CD133+/CD44+ were more vulnerable to meisoindigo, which could be mimicked by LKB1 siRNAs. Our results provide the first evidence, to our knowledge, that LKB1 sustains the CSC population in PDACs and demonstrate a clear benefit of meisoindigo in treatment of gemcitabine-resistant cells. This novel mechanism may provide a promising new treatment option for PDAC.
Item Description:Gesehen am 30.04.2020
Physical Description:Online Resource
ISSN:1878-0261
DOI:10.1016/j.molonc.2016.01.008

Similar Items